In the middle of Lexeo’s 2023 IPO, gene-therapy competitor Rocket Pharmaceuticals filed a trade secret misappropriation lawsuit against Lexeo in the Southern District of New York. S&C helped Lexeo navigate an expedited internal investigation, allowing for a successful IPO, and then turned to defending Lexeo in the biotech litigation on the merits. After full discovery, S&C recently obtained a voluntary dismissal with prejudice of all claims, successfully ending this litigation for Lexeo as it proceeds with clinical trials for multiple drug candidates.
The S&C team was led by Dustin Guzior, Ann-Elizabeth Ostrager and Alexander Gross and included Stephen Elliott, Brittany Bruns, Justin Smallwood, Navraj Dhillon, Nikko Price, Conor Ferrall, Haley Sanders, Emma Burke, Coulson Canty, Sarah Fornshell and Dylan Gaffney. Medhi Ansari, Rachel Yu and Philippe Schiff advised on the settlement agreement.